Zobrazeno 51 - 60
of 211
pro vyhledávání: '"Shira Zelber-Sagi"'
Autor:
Shira Zelber-Sagi
Publikováno v:
Seminars in liver disease. 41(3)
The key factor in preventing and treating nonalcoholic fatty liver disease (NAFLD) is a holistic lifestyle modification approach, encompassing diet based on healthy eating patterns of unprocessed foods, exercise, balanced drinking, and smoking habits
Autor:
Shira Zelber-Sagi, Oren Shibolet, Revital Kariv, Naomi Fliss-Isakov, Dana Ivancovsky-Wajcman, Itay Bentov, Muriel Webb
Publikováno v:
Liver international : official journal of the International Association for the Study of the LiverREFERENCES. 41(11)
Background & aims High consumption of ultra-processed food (UPF) is associated with mortality and chronic morbidity but has not been studied concerning to non-alcoholic fatty liver disease (NAFLD). We aimed to test the association of UPF consumption
Autor:
Haotian Ruan, Samah Hayek, Matthew Lee Smith, Samuel D. Towne, Rui Li, Xiaoqing Jiang, Shira Zelber-Sagi, Anran Tan, Xiaojun Liu, Zhaokang Yuan, Jay E. Maddock
Publikováno v:
International Journal of Environmental Research and Public Health
Volume 18
Issue 11
International Journal of Environmental Research and Public Health, Vol 18, Iss 6113, p 6113 (2021)
Volume 18
Issue 11
International Journal of Environmental Research and Public Health, Vol 18, Iss 6113, p 6113 (2021)
Despite near universal health insurance coverage in China, populations with low incomes may still face barriers in access and utilization of affordable health care. We aimed to identify the likelihood of forgone medical care due to cost by surveying
Autor:
Eran Elinav, Shira Zelber-Sagi, Smadar Shilo, Michal Rein, Eran Segal, Orly Ben-Yacov, Anastasia Godneva
Publikováno v:
Diabetes. 70
Dietary modifications are crucial for the management of newly-diagnosed type-2 diabetes (T2D) and prevention of its health complications, but many patients fail to achieve clinical goals with diet alone. We previously developed a machine-learning alg
Autor:
Jeffrey V, Lazarus, Quentin M, Anstee, Hannes, Hagström, Kenneth, Cusi, Helena, Cortez-Pinto, Henry E, Mark, Michael, Roden, Emmanuel A, Tsochatzis, Vincent Wai-Sun, Wong, Zobair M, Younossi, Shira, Zelber-Sagi, Manuel, Romero-Gómez, Jörn M, Schattenberg
Publikováno v:
Nature reviews. Gastroenterologyhepatology. 18(10)
Non-alcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease globally. Despite the increased demand placed on health-care systems, little attention has been given to the design and implementation of efficient and effect
Autor:
Dana Ivancovsky Wajcman, Naomi Fliss-Isakov, Laura Sol Grinshpan, Muriel Webb, Oren Shibolet, Revital Kariv, Shira Zelber-Sagi
Publikováno v:
Journal of Hepatology. 77:S148
Autor:
Shira Zelber-Sagi, Rebecca Dorner, Giulio Marchesini, Marko Korenjak, Christos Lionis, Jeffrey V. Lazarus, Sven Francque, Achim Kautz, Luca Busetto, José Willemse, G. Koek, Dror Dicker, Kate Hallsworth, Shlomo Vinker, Gema Frühbeck, Euan Woodward, Mehmet Ungan, Juan M. Mendive, Martine Walmsley
Publikováno v:
JHEP Reports
JHEP Reports, Vol 3, Iss 5, Pp 100322-(2021)
JHEP Reports, 3(5):100322. Elsevier BV
JHEP Reports, Vol 3, Iss 5, Pp 100322-(2021)
JHEP Reports, 3(5):100322. Elsevier BV
This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawarene
Publikováno v:
Clinics in liver disease. 25(2)
Malnutrition and sarcopenia that lead to functional deterioration, frailty, and increased risk for complications and mortality are common in cirrhosis. Sarcopenic obesity, which is associated with worse outcomes than either condition alone, may be ov
Autor:
Manuel Romero-Gómez, Patrizia Carrieri, Mattias Ekstedt, Shira Zelber-Sagi, Katja Novak, Vlad Ratziu, Quentin M. Anstee, Frank Tacke, Adam Palayew, Jeffrey V. Lazarus, Helena Cortez-Pinto, Giulio Marchesini
Publikováno v:
JHEP Reports Innovation in Hepatology
JHEP Reports Innovation in Hepatology, Elsevier, 2021, 3 (2), pp.100234. ⟨10.1016/j.jhepr.2021.100234⟩
Digital.CSIC. Repositorio Institucional del CSIC
instname
JHEP Reports
JHEP Reports, Vol 3, Iss 2, Pp 100234-(2021)
JHEP Reports Innovation in Hepatology, Elsevier, 2021, 3 (2), pp.100234. ⟨10.1016/j.jhepr.2021.100234⟩
Digital.CSIC. Repositorio Institucional del CSIC
instname
JHEP Reports
JHEP Reports, Vol 3, Iss 2, Pp 100234-(2021)
[Background & Aims] Non-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity, metabolic syndrome, and diabetes, is a highly prevalent emerging condition that can be optimally managed through a multidisciplinary patient-cent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::237265ca3a905978c88b2731dd069191
https://hal.sorbonne-universite.fr/hal-03174867
https://hal.sorbonne-universite.fr/hal-03174867
Autor:
Ivo Boškoski, Federico Salomone, Giovanni Magrì, Fabio Galvano, Walter Currenti, Shira Zelber-Sagi
Publikováno v:
Liver international : official journal of the International Association for the Study of the LiverREFERENCES. 41(9)
BACKGROUND AND AIMS Effective therapy for clinically significant fibrosis in nonalcoholic fatty liver disease (NAFLD) is an unmet need. Data on the effectiveness of endoscopic placement of intragastric balloon (IGB) in patients with NAFLD are limited